• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Compass Therapeutics Inc. (Amendment)

    2/13/23 5:20:40 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CMPX alert in real time by email
    SC 13G/A 1 tm236260d2_sc13ga.htm SC 13G/A

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Schedule 13G
    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

    (Amendment No. 1)*

     

    Compass Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001

    (Title of Class of Securities)

     

    20454B104

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    x Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following pages)

     

    Page 1 of 12

     

    Exhibit Index on Page 11

     

     

      

     

    CUSIP # 20454B104 Page 2 of 12

     

    1 NAME OF REPORTING PERSONS      Foresite Capital Fund V, L.P. (“FCF V”)  
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)    ¨    (b)    x
    3 SEC USE ONLY  
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    4,400,000 shares, except that Foresite Capital Management V, LLC (“FCM V”), the general partner of FCF V, may be deemed to have sole power to vote these shares, and James B. Tananbaum (“Tananbaum”), the managing member of FCM V, may be deemed to have sole power to vote these shares.
    6 SHARED VOTING POWER
    See response to row 5.
    7

    SOLE DISPOSITIVE POWER

    4,400,000 shares, except that FCM V, the general partner of FCF V, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to dispose of these shares.

     

    8 SHARED DISPOSITIVE POWER
    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
    REPORTING PERSON
    4,400,000
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES
    ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    3.5%
    12 TYPE OF REPORTING PERSON PN

     

     

    CUSIP # 20454B104 Page 3 of 12

     

    1 NAME OF REPORTING PERSONS      Foresite Capital Management V, LLC (“FCM V”)  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     
    (a)    ¨    (b)    x
    3 SEC USE ONLY  
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    4,400,000 shares, all of which are directly owned by FCF V.  FCM V, the general partner of FCF V, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to vote these shares.
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    4,400,000 shares, all of which are directly owned by FCF V.  FCM V, the general partner of FCF V, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to dispose of these shares.
    8 SHARED DISPOSITIVE POWER
    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
    REPORTING PERSON
    4,400,000
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES
    ¨ 
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
    3.5%
    12 TYPE OF REPORTING PERSON OO

     

     

    CUSIP # 20454B104 Page 4 of 12

     

    1 NAME OF REPORTING PERSONS      Foresite Capital Opportunity Fund V, L.P. (“FCF Opp V”)  
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)    ¨    (b)    x
    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH
    5

    SOLE VOTING POWER

    1,554,250 shares, except that Foresite Capital Opportunity Management V, LLC (“FCM Opp V”), the general partner of FCF Opp V, may be deemed to have sole power to vote these shares, and James B. Tananbaum (“Tananbaum”), the managing member of FCM Opp V, may be deemed to have sole power to vote these shares.

    6

    SHARED VOTING POWER

    See response to row 5.

    7

    SOLE DISPOSITIVE POWER

    1,554,250 shares, except that FCM Opp V, the general partner of FCF Opp V, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM Opp V, may be deemed to have sole power to dispose of these shares.

     

    8

    SHARED DISPOSITIVE POWER

    See response to row 7.

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH

    REPORTING PERSON

    1,554,250
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)

    EXCLUDES CERTAIN SHARES

    ¨ 
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    1.2%
    12 TYPE OF REPORTING PERSON PN

     

     

    CUSIP # 20454B104 Page 5 of 12

     

    1 NAME OF REPORTING PERSONS      Foresite Capital Opportunity Management V, LLC (“FCM Opp V”)  
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)    ¨    (b)    x
    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH
    5

    SOLE VOTING POWER

    1,554,250 shares, all of which are directly owned by FCF Opp V.  FCM Opp V, the general partner of FCF Opp V, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM Opp V, may be deemed to have sole power to vote these shares.

    6

    SHARED VOTING POWER

    See response to row 5.

    7

    SOLE DISPOSITIVE POWER

    1,554,250 shares, all of which are directly owned by FCF Opp V.  FCM Opp V, the general partner of FCF Opp V, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM Opp V, may be deemed to have sole power to dispose of these shares.

    8

    SHARED DISPOSITIVE POWER

    See response to row 7.

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH

    REPORTING PERSON

    1,554,250
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)

    EXCLUDES CERTAIN SHARES

    ¨ 
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    1.2%
    12 TYPE OF REPORTING PERSON OO

     

     

    CUSIP # 20454B104 Page 6 of 12

     

    1 NAME OF REPORTING PERSONS      James B. Tananbaum (“Tananbaum”)  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     
    (a)    ¨    (b)    x
    3 SEC USE ONLY  
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    United States
     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    5,954,250 shares, of which 4,400,000 shares are directly owned by Foresite Capital Fund V, L.P. (“FCF V”) and 1,554,250 shares are directly owned by Foresite Capital Opportunity Fund V, L.P. (“FCF Opp V”).  Tananbaum is the managing member of each of Foresite Capital Management V, LLC (“FCM V”), which is the general partner of FCF V, and Foresite Capital Opportunity Management V, LLC (“FCM Opp V”), which is the general partner of FCF Opp V.  Tananbaum may be deemed to have sole power to vote these shares.
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    5,954,250 shares, of which 4,400,000 shares are directly owned by FCF V and 1,554,250 shares are directly owned by FCF Opp V.  Tananbaum is the managing member of each of FCM V, which is the general partner of FCF V, and FCM Opp V, which is the general partner of FCF Opp V.  Tananbaum may be deemed to have sole power to dispose of these shares.
    8 SHARED DISPOSITIVE POWER
    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
    REPORTING PERSON
    5,954,250
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES
    ¨ 
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
    4.7%
    12 TYPE OF REPORTING PERSON IN

     

     

    CUSIP # 20454B104 Page 7 of 12

     

    ITEM 1(A).NAME OF ISSUER

    Compass Therapeutics, Inc. (the “Issuer”)

     

    ITEM 1(B).ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

    80 Guest Street, Suite 601
    Boston, MA 02135

     

    ITEM 2(A).NAME OF PERSONS FILING

    This Schedule is filed by Foresite Capital Fund V, L.P., a Delaware limited partnership (“FCF V”), Foresite Capital Management V, LLC, a Delaware limited liability company (“FCM V”), Foresite Capital Opportunity Fund V, L.P., a Delaware limited partnership (“FCF Opp V”), Foresite Capital Opportunity Management V, LLC, a Delaware limited liability company (“FCM Opp V”), and James B. Tananbaum. The foregoing entities and individuals are collectively referred to as the “Reporting Persons.”

     

    ITEM 2(B).ADDRESS OF PRINCIPAL OFFICE

     

    The address for each of the Reporting Persons is:

     

    c/o Foresite Capital Management

    900 Larkspur Landing Circle, Suite 150
    Larkspur, California 94939
     

    ITEM 2(C).CITIZENSHIP

    See Row 4 of cover page for each Reporting Person.

     

    ITEM 2(D).TITLE OF CLASS OF SECURITIES

    Common Stock, par value $0.0001

     

    ITEM 2(E)CUSIP NUMBER

    20454B104

     

    ITEM 3.If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

     

    CUSIP # 20454B104 Page 8 of 12

     

    ITEM 4.OWNERSHIP

     

    The following information with respect to the ownership of the Common Stock of the Issuer by the persons filing this Statement is provided as of December 31, 2022:

     

    (a)Amount beneficially owned:

    See Row 9 of cover page for each Reporting Person.

     

    (b)Percent of Class:

    See Row 11 of cover page for each Reporting Person.

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:

    See Row 5 of cover page for each Reporting Person.

     

    (ii)Shared power to vote or to direct the vote:

     

    See Row 6 of cover page for each Reporting Person.

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    See Row 7 of cover page for each Reporting Person.

     

    (iv)Shared power to dispose or to direct the disposition of:

    See Row 8 of cover page for each Reporting Person.

     

    ITEM 5.OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:     x

     

    ITEM 6.OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

    Under certain circumstances set forth in the limited partnership agreements of FCF V and FCF Opp V and the limited liability company agreements of FCM V and FCM Opp V, the partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from the sale of, shares of the Issuer directly or indirectly owned by each such entity of which they are a partner or member.

     

    ITEM 7.IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

    Not applicable.

     

    ITEM 8.IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

    Not applicable

     

    ITEM 9.NOTICE OF DISSOLUTION OF GROUP.

    Not applicable

     

     

    CUSIP # 20454B104 Page 9 of 12

     

    ITEM 10.CERTIFICATION.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

    CUSIP # 20454B104 Page 10 of 12

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

       
    Date: February 10, 2023  
       
      FORESITE CAPITAL FUND V, L.P.
       
      By: FORESITE CAPITAL MANAGEMENT V, LLC
      Its: General Partner
       
      By: /s/ James B. Tananbaum
      Name: James B. Tananbaum
      Title:  Managing Member
       
      FORESITE CAPITAL MANAGEMENT V, LLC
       
      By: /s/ James B. Tananbaum
      Name: James B. Tananbaum
      Title:  Managing Member
       
       
      FORESITE CAPITAL OPPORTUNITY FUND V, L.P.
       
      By: FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLC
      Its:  General Partner
       
      By: /s/ James B. Tananbaum
      Name: James B. Tananbaum
      Title:  Managing Member
       
      FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLC
       
      By: /s/ James B. Tananbaum
      Name: James B. Tananbaum
      Title:  Managing Member
       
      JAMES B. TANANBAUM
       
      By: /s/ James B. Tananbaum
      Name: James B. Tananbaum

     

     

    CUSIP # 20454B104 Page 11 of 12

     

    EXHIBIT INDEX

     

      Found on
    Sequentially
    Exhibit Numbered Page
       
    Exhibit A:  Agreement of Joint Filing 12
       

     

     

    CUSIP # 20454B104 Page 12 of 12

     

    exhibit A

     

    Agreement of Joint Filing

     

    The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock of the Issuer shall be filed on behalf of each of the undersigned. Note that a copy of the applicable Agreement of Joint Filing is already on file with the appropriate agencies.

     

     

     

    Get the next $CMPX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CMPX

    DatePrice TargetRatingAnalyst
    4/2/2025$6.00Market Perform → Outperform
    Leerink Partners
    2/24/2025$12.00Buy
    Guggenheim
    2/19/2025$12.00Overweight
    Piper Sandler
    12/23/2024$32.00Buy
    D. Boral Capital
    11/15/2024$5.00 → $4.00Outperform → Market Perform
    Leerink Partners
    9/16/2024$5.00Neutral → Buy
    Ladenburg Thalmann
    1/31/2023$8.00Buy
    Jefferies
    1/27/2023$9.00Buy
    Stifel
    More analyst ratings

    $CMPX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Compass Therapeutics Inc.

      SCHEDULE 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)

      5/15/25 4:15:24 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Compass Therapeutics Inc.

      10-Q - Compass Therapeutics, Inc. (0001738021) (Filer)

      5/8/25 8:01:09 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Compass Therapeutics, Inc. (0001738021) (Filer)

      5/8/25 8:00:29 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Schuetz Thomas J. bought $21,100 worth of shares (10,000 units at $2.11), increasing direct ownership by 0.15% to 6,480,825 units (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      5/27/25 3:24:21 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gen Counsel & Corporate Sec Anderman Jonathan bought $30,800 worth of shares (20,000 units at $1.54), increasing direct ownership by 2,000% to 21,000 units (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      4/8/25 9:30:55 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF ACCOUNTING OFFICER Lerner Neil bought $28,400 worth of shares (20,000 units at $1.42), increasing direct ownership by 7% to 320,000 units (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      4/8/25 9:25:57 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMPX
    Leadership Updates

    Live Leadership Updates

    See more
    • Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

      BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024. Mr. Shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor. "We are delighted to welcome Barry to Compass during this pivotal and exciting time for the company," said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. "We have severa

      12/10/24 8:00:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics Announces CEO Transition

      BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Schuetz, M.D., Ph.D., President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, effective May 28, 2024. Vered Bisker-Leib, Ph.D., M.B.A., has stepped down as Chief Executive Officer and as a member of the Board of Directors of the Company, effective May 28, 2024. Dr. Bisker-Leib will continue to be available

      5/28/24 4:10:20 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

      Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC). Top line data is expected in the first half of 2024Continue to enroll in a U.S. Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC). Initial data expected in the third quarter of 2023Presented results of a Phase 2 study of CTX-009 in combination with paclitaxel in patients with BTC at the 2023 ASCO GI Cancers SymposiumExpanded the management team with the appointment of Minori Rosales, M.D. PhD, as Senior Vice President & Head of Clinical DevelopmentAppointed Richard Lindahl, M.B.A., EVP & CFO of Emergent BioSolutio

      5/4/23 8:30:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMPX
    Financials

    Live finance-specific insights

    See more

    $CMPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009

      Call scheduled for Wednesday, May 4, 2022 at 8:00 a.m. ET Key Opinion Leader to Participate BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it will host a webinar on Wednesday, May 4, 2022 at 8:00 a.m. ET to review clinical data from its ongoing Phase 2 clinical trial assessing CTX-009. A Key Opinion Leader will join management for the discussion. Webinar Details:   Date:  May 04, 2022   Time: 8:00 a.m. ET   Webcast: Registration Link   Replay availability: A replay will be available on the Compass website for 6 months. Abo

      5/3/22 4:01:00 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • OTC Markets Group Announces Quarterly Index Performance and Rebalancing

      NEW YORK, July 20, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX:OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced the second quarter 2021 performance and quarterly rebalancing of the OTCQX® and OTCQB® indexes, including the OTCQX Canada Index and the OTCQX Dividend Index. The OTCQX Composite Index (.OTCQX), a benchmark for the overall OTCQX Best Market, was up 3.9% in the second quarter. Ninety-two new companies were added to the index, including: AirBoss of America Corp. (OTCQX:ABSSF); Blackrock Silver Corp. (OTCQX:BKRRF); Belo Sun Mining Corp. (OTCQX:BSXGF); Caldwell Partners International Inc. (OTCQX:CWLPF); Graphite One Inc. (OTCQX:GPHOF)

      7/20/21 4:00:00 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Compass Therapeutics Inc.

      SC 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)

      11/14/24 10:00:35 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Compass Therapeutics Inc.

      SC 13G - Compass Therapeutics, Inc. (0001738021) (Subject)

      8/2/24 4:15:57 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Compass Therapeutics Inc. (Amendment)

      SC 13D/A - Compass Therapeutics, Inc. (0001738021) (Subject)

      3/22/24 4:59:51 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMPX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

      BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 3-5, 2025. Fireside Chat DetailsDate: Thursday, June 5, 2025Time: 11:05 – 11:35 AM ETWebcast Link: https://wsw.com/webcast/jeff319/cmpx/1867328 Virtual/Replay availability: The fireside chat will be archived for 90 days on Compass' Events page. About Compass TherapeuticsCompass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company devel

      5/28/25 8:00:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

      Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate (ORR), including one complete response, compared to a 5.3% ORR for paclitaxel alone, in patients with BTC treated in the second-line setting. First patient dosed and actively enrolling patients in an Investigator Sponsored Trial (IST) evaluating tovecimig in patients with BTC in the first-line setting.Successfully completed a pre-IND meeting for CTX-10726 (PD-1 x VEGF-A bispecific antibody), maintaining progress towards expected Q4 2025 IND filing and 2026 clinical data.Advanced the

      5/8/25 8:00:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics to Participate in Upcoming May Investor Events

      BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of May. Details are as follows: The Citizens Life Sciences ConferenceLocation: New York, NYDate: Thursday, May 8, 2025 Time: 1:30 PM ETWebcast Link: https://wsw.com/webcast/jmp65/cmpx/1692592 H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQLocation: New York, NYDate: Tuesday, May 20, 2025 Time: 11:30AM ETWebcast Link: https://journey.ct.events/view/29729b86-5109-46dc-a93b-1cf3

      5/6/25 8:00:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Compass Therapeutics upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Compass Therapeutics from Market Perform to Outperform and set a new price target of $6.00

      4/2/25 8:43:28 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on Compass Therapeutics with a new price target

      Guggenheim initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $12.00

      2/24/25 7:07:23 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Compass Therapeutics with a new price target

      Piper Sandler initiated coverage of Compass Therapeutics with a rating of Overweight and set a new price target of $12.00

      2/19/25 7:01:43 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Schuetz Thomas J. bought $21,100 worth of shares (10,000 units at $2.11), increasing direct ownership by 0.15% to 6,480,825 units (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      5/27/25 3:24:21 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Gordon Carl L sold $5,678,571 worth of shares (3,571,428 units at $1.59) (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      4/11/25 7:37:43 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Orbimed Advisors Llc sold $5,678,571 worth of shares (3,571,428 units at $1.59) (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      4/11/25 7:24:24 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care